We spoke to Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, about the CARPALL (NCT02443831) and AMELIA (NCT03289455) trials. CARPALL is looking at CD19 CAR-T for young patients with relapsed acute lymphoblastic leukemia (ALL), while AMELIA is investigating CD19/22 CAR T-cells (AUTO3) for the treatment of relapsed/refractory B-cell ALL. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.